Bio simulation Market to Surge to USD 16.69 Billion by 2032 Riding a 16.23% CAGR on Rising Biologics R&D, AI-Enabled Modelling and Demand for Cost-Efficient Drug Development
 Biosimulation Market  remarkable growth is being driven by a confluence of factors: rapid expansion in biologics and biosimilar development, the escalating burden of chronic diseases, rising demand for precision medicine, and regulatory momentum favoring in-silico simulation to streamline drug development, reduce costs, and accelerate time-to-market. Quick Insights...
0 Comments 0 Shares 6 Views 0 Reviews